1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
HYUNDAI BIOLAND Co.,Ltd.

HYUNDAI BIOLAND Co.,Ltd.

KKRX:052260
4,325.00
KRW
-80.00
(-1.82%)
416.00EPS
9.64P/E
120.30BMarket Cap
HYUNDAI BIOLAND Co.,Ltd.
KRX:052260
(Korea Stock Exchange)

Recent

price

4,325.00

P/E

ratio

9.64

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
2,083.83
2,281.24
2,435.98
2,369.39
2,565.41
2,696.62
3,258.59
3,420.29
3,352.44
3,542.43
2,963.2
3,426.39
3,309.05
3,223.99
3,981.78
4,132.82
4,501.27
Revenue per Share
419
457.34
338
324.5
352
359.5
414
399.5
501.5
361.5
-451.5
-389.5
159
268.54
190
8
416
Basic EPS, GAAP
339.43
-471.88
139.62
416.44
219.84
130.19
-60.36
-91.06
66.13
-356.86
45.61
604.1
218.93
-23.42
22.53
487.92
505.56
Free Cash Flow per Basic Share
75.04
100
100.07
100.07
99.97
124.99
124.94
125.06
124.98
149.95
174.99
50
35.04
35
34.98
66.5
- -
Dividend per Share
2,406.14
3,109.72
3,355.13
3,580.03
3,816.09
4,060.53
4,351.07
4,593.87
4,963.53
5,190.78
4,574.28
4,178.33
4,309.55
4,532.8
4,600.28
4,538.22
4,654.76
Book Value per Share
2,402.73
3,043.38
3,286.2
3,495.5
3,746.42
3,991.35
4,273.23
4,507.54
4,773.6
4,805.13
4,137.04
3,801.37
3,909.66
4,124.92
4,472.42
4,410.53
4,506.61
Tangible Book Value per Share
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
32
30
Basic Weighted Avg Shares
62,482
68,437
73,026
71,030
76,988
80,902
97,808
102,557
100,589
106,311
88,899
102,802
99,154
96,720
119,519
130,505
135,038
Sales/Revenue/Turnover
24.1
21.98
21.06
18.52
20.85
17.55
16.44
15.62
16.96
13.6
-9.97
10.37
9.13
13.92
13.69
9.77
9.58
Operating Margin (%)
2,639
3,353
7,046
6,472
5,552
3,845
4,295
5,765
6,184
6,501
5,976
8,561
6,328
6,301
6,518
4,880
4,744
Depreciation Expense
12,563
13,720
10,133
9,728
10,563
10,785
12,426
11,979
15,047
10,849
-13,545
-11,686
4,764
8,056
5,703
253
12,480
Net Income, GAAP
14.27
10.89
29.3
13.03
20.65
21.13
27.53
22.61
6.15
16.51
- -
- -
30.39
20.64
22.5
6.62
0.64
Effective Tax Rate (%)
20.11
20.05
13.88
13.7
13.72
13.33
12.7
11.68
14.96
10.2
-15.24
-11.37
4.81
8.33
4.77
0.19
9.24
Profit Margin (%)
31,744
25,685
45,415
29,312
46,559
40,372
54,407
42,976
49,847
50,657
21,656
17,253
25,072
32,797
51,386
63,887
67,977
Working Capital
1,269
14,110
31,000
1,000
14,000
3,658
21,000
12,744
18,043
27,900
14,922
218
206
374
231
134
188
LT Debt
72,184
93,292
100,654
107,401
114,483
121,816
130,532
137,816
148,906
155,724
137,229
125,350
129,287
135,984
138,008
136,147
139,643
Total Equity
17.54
14.18
8.8
8.51
9.59
8.17
7.88
7.75
9.24
6.38
- -
- -
3.88
6.35
7.32
7.37
8.82
Return on Invested Capital (%)
17.55
14.84
8.89
8.1
8.55
8.27
8.75
7.9
9.14
6.12
- -
- -
3.49
5.09
3.56
0.43
8.77
Return on Capital (%)
18.75
16.58
10.45
9.35
9.52
9.13
9.85
8.93
10.5
7.12
-9.25
-8.9
3.74
6.07
4.16
0.18
9.32
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
10,333
10,299
6,286
LT Borrowings
- -
- -
- -
LT Finance Leases
213
134
188
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
147,450
128,850
120,300

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
90,731
92,105
87,434
Cash, Cash Equivalents & STI
21,828
23,254
17,265
Accounts Receivable, Net
19,462
14,966
21,713
Inventories
48,610
52,707
47,205
Total Current Liabilities
25,857
28,218
19,457
Payables & Accruals
- -
- -
- -
ST Debt
10,333
10,299
6,286
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.33%
-0.04%
-1.35%
Free Cash Flow
201.09%
606.35%
2,178.02%
Net Income, GAAP
-42.57%
-42.04%
-95.57%
Sales/Revenue/Turnover
5.55%
8.48%
9.19%
Total Cash Common Dividend
- -
- -
100%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28,805
32,850
31,973
21,494
119,519
2025
33,699
34,613
35,478
26,716
130,505
2026
38,232
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
106.5
154
102
-172.01
190
2025
-234
169.84
131.41
-58.94
8
2026
173.69
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
34.98
2025
- -
- -
- -
- -
66.5
2026
- -
- -
- -
- -
- -
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
Aether Industries Ltd. (NSE:AETHER)
AARTI Industries Ltd (NSE:AARTIIND)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
HYUNDAI BIOLAND Co.,Ltd. is a South Korea-based biotechnology company engaged in the development, manufacturing, and distribution of natural active ingredients and biomaterials for the cosmetics, health functional food, and biomedical industries. Founded in 1995 and headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, the company operates as the core healthcare and life sciences affiliate of the Hyundai Department Store Group. The company operates through three primary business divisions: Cosmetic Ingredients, Health Supplements (Nutraceuticals), and Biomedical Materials. In the Cosmetic Ingredients division, HYUNDAI BIOLAND manufactures a portfolio of over 500 botanical extracts, bioactive compounds, and functional raw materials utilizing natural extraction, separation, fermentation, and bioconversion technologies; its product offerings include sodium hyaluronate (Bio-Sodium Hyaluronate); oil-soluble hyaluronic acid formulations (HYALWAX); skin-soothing botanical extracts (including Portulaca Oleracea extract); whitening and brightening agents (including arbutin); and barrier-enhancing plant-derived ceramides (including Citron Ceramide). In the Health Supplements division, the company manufactures functional health food ingredients aimed at immunity enhancement, joint health, body fat management, and digestive wellness; it also provides commercial development and finished product distribution services. In the Biomedical Materials division, the company develops regenerative medical devices and collagen-based matrices for dental, orthopedic, and dermatological applications; primary products include resorbable collagen membranes (OssGuide and T-Gen) utilized in guided bone regeneration (GBR) and periodontal tissue repair; collagen wound healing dressings; and medical-grade sodium hyaluronate. HYUNDAI BIOLAND serves multinational cosmetics manufacturers, pharmaceutical enterprises, dental clinics, and dietary supplement providers across more than 35 countries. The company operates multiple research and manufacturing complexes in South Korea, including facilities in Osong, Ochang, Cheonan, and Ansan, as well as an international manufacturing facility in Haimen, China. In recent strategic developments, HYUNDAI BIOLAND has significantly expanded its consumer healthcare business through a strategic alliance with Nestlé Health Science, securing exclusive South Korean import and distribution rights for global nutritional supplement brands, including Solgar, Vital Proteins, Nuun, and Egmont Manuka Honey, while opening dedicated retail health stores incorporating artificial intelligence-driven diagnostic tools. Furthermore, the company continues to expand its global bio-ingredients commercialization network through distribution agreements with international partners such as DKSH, alongside the continuous rollout of next-generation bio-fermentation and oil-soluble active cosmetic ingredients.